Tuesday, February 15, 2022

< + > The Road To 340B Was Paved With Good Intentions So Why Are Drug Companies Looking For An Off Ramp?

From a $5 billion program in 2014 to a $30 billion program in 2019, 340B saw a 47% compound annual growth rate in five years, significantly outpacing other government pricing programs. Current estimates place it at about $34 billion today.

No comments:

Post a Comment

< + > Hybrid Intelligence with Carta Healthcare – Life Sciences Today Podcast Episode 33

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Aaron Brauser, Ge...